Page last updated: 2024-11-05

piperidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Piperidine is a heterocyclic organic compound with the formula (CH2)5NH. It is a colorless liquid with an ammonia-like odor. It is an important building block in organic synthesis and is used in the production of a wide range of pharmaceuticals and agrochemicals. Piperidine is a highly versatile compound with a wide range of applications. It is used in the synthesis of various pharmaceutical drugs, including antihistamines, antidepressants, and analgesics. Piperidine is also used in the production of agrochemicals, such as insecticides and herbicides. Furthermore, it has applications in the synthesis of polymers, dyes, and other industrial chemicals. Piperidine is a key component in the synthesis of various natural products, including alkaloids, such as nicotine, coniine, and piperine. These alkaloids exhibit diverse biological activities, including neurotoxicity, insecticidal properties, and medicinal effects. Piperidine is a common motif found in drug candidates, and its synthetic versatility has made it a valuable tool for medicinal chemists. Piperidine derivatives are studied extensively for their potential therapeutic applications. Research efforts focus on understanding the structure-activity relationships of piperidine-containing compounds and developing novel drugs for various diseases, including cancer, Alzheimer's disease, and Parkinson's disease.'

Cross-References

ID SourceID
PubMed CID8082
CHEMBL ID15487
CHEBI ID18049
MeSH IDM0101912

Synonyms (74)

Synonym
pentamethyleneamine
azinane
CHEBI:18049 ,
pentamethylenimine
PIP ,
cyclopentimine
pentamethyleneimine
NCIMECH_000312
cypentil
perhydropyridine
piperidine [un2401] [corrosive]
fema no. 2908
ccris 967
hsdb 114
un2401
hexazane
pyridine, hexahydro-
piperidin [german]
einecs 203-813-0
ai3-24114
inchi=1/c5h11n/c1-2-4-6-5-3-1/h6h,1-5h
110-89-4
azacyclohexane
C01746
hexahydropyridine
PIPERIDINE ,
piperidine, >=99%, fcc
piperidine, reagentplus(r), 99%
piperidine, >=99.5%, purified by redistillation
NCIOPEN2_007828
CHEMBL15487 ,
FT-0655373
bdbm50026449
AKOS002309795
NCGC00248946-01
piperidin
NCGC00258727-01
dtxsid6021165 ,
tox21_201175
dtxcid101165
cas-110-89-4
P0453
unii-67i85e138y
piperidine [un2401] [corrosive]
67i85e138y ,
ec 203-813-0
piperidine [fcc]
piperidine [fhfi]
piperidine [mi]
piperidine [hsdb]
piperidine [who-dd]
gtpl5477
pyperidine
piperadine
piperdine
un 2401
mfcd00005979
piperidine (peptide grade)
piperidine, puriss. plus, >=99.5% (gc)
piperidine, purum, >=96.0% (gc/t)
piperidine, analytical standard
piperidine, puriss. p.a., >=99.0% (gc/t)
piperidine, saj first grade, >=99.0%
piperidine, biotech. grade, >=99.5%
stratospheres(tm) pl-pip (piperidine) resin, 50-100 mesh, extent of labeling: 3.0-4.0 mmol/g loading, 1 % cross-linked
piperidine, >=99%, fg
fema 2908
piperidine on rasta resin
Q410234
STR00031
n-piperidine
89014-30-2
piperidine, homopolymer
pentamethseneimine

Research Excerpts

Overview

Piperidine is a nitrogen-containing heterocyclic moiety that exhibits an array of pharmacological properties. Piperidines are a relatively novel class of calcium channel blockers which act at a unique receptor site associated with the calcium channel alpha1 subunit.

ExcerptReferenceRelevance
"Piperidine is a nitrogen-containing heterocyclic moiety that exhibits an array of pharmacological properties."( Piperidine Nucleus as a Promising Scaffold for Alzheimer's Disease: Current Landscape and Future Perspective.
Bhardwaj, M; Grover, P; Malhotra, A; Mehta, L; Rohilla, S, 2023
)
3.07
"The piperidine ring is a widespread motif in several natural bioactive alkaloids of both vegetal and marine origin. "( Total Synthesis of (-)-Anaferine: A Further Ramification in a Diversity-Oriented Approach.
Bonandi, E; Passarella, D; Perdicchia, D; Tedesco, G, 2020
)
1.12
"Piperidine is an important pharmacophore, a privileged scaffold and an excellent heterocyclic system in the field of drug discovery which provides numerous opportunities in studying/exploring this moiety as an anticancer agent by acting on various receptors of utmost importance. "( Recent advancement of piperidine moiety in treatment of cancer- A review.
Alam, MI; Alam, O; Goel, P; Iqbal, M; Naim, MJ; Nawaz, F, 2018
)
2.24
"Piperidine is a 1-ring heterocyclic compound formed from the polyamine cadaverine in the human intestine. "( Inhibition of Salmonella typhimurium enteropathogenicity by piperidine, a metabolite of the polyamine cadaverine.
Köhler, H; Maurelli, AT; McCormick, BA; Rodrigues, SP, 2002
)
2
"Piperidine was found to be a good desilylation reagent."( First synthesis of etidronate partial amides starting from PCl3.
Järvinen, T; Niemi, R; Peräkylä, M; Turhanen, PA; Vepsäläinen, JJ, 2003
)
1.04
"Piperidines are a relatively novel class of calcium channel blockers which act at a unique receptor site associated with the calcium channel alpha1 subunit. "( Cytoplasmic determinants of piperidine blocking affinity for N-type calcium channels.
Zamponi, GW, 1999
)
2.04
"Piperidine (Pip) is a normal constituent in mammalian brain, affects synaptic mechanism in the CNS, and influences neural mechanisms governing regulation of emotional behavior and extrapyramidal function. "( [Piperidine in the brain: its neurobiological significance].
Kasé, Y; Miyata, T; Okano, Y; Takahama, K, 1989
)
2.63

Treatment

Piperidine treatment enhanced the DNA damage greatly. Hydrazobenzene caused base modification and liberation. Pretreatment with piperidine in doses greater than 2 X 10(-4)M depressed the transient ACh-induced ICl.

ExcerptReferenceRelevance
"Piperidine treatment enhanced the DNA damage greatly, suggesting that hydrazobenzene caused base modification and liberation."( Copper-dependent DNA damage induced by hydrazobenzene, an azobenzene metabolite.
Hiraku, Y; Kawanishi, S; Murata, M; Ohnishi, S; Oikawa, S, 2000
)
1.03
"Pretreatment with piperidine in doses greater than 2 X 10(-4)M depressed the transient ACh-induced ICl but had little effect on the persistent ICl."( Piperidine discriminates between the transient and the persistent components of the ACh-induced chloride current in Aplysia neurons.
Klee, MR; Takahama, K, 1990
)
2.05

Toxicity

ExcerptReferenceRelevance
" The present paper summarizes the occurrence of alkaloids in the food chain, their mode of action and possible adverse effects including a safety assessment."( Alkaloids in the human food chain--natural occurrence and possible adverse effects.
Dusemund, B; Koleva, II; Rietjens, IM; Soffers, AE; van Beek, TA, 2012
)
0.38

Pharmacokinetics

ExcerptReferenceRelevance
" Here, we analyzed the occupancy of 5-HT1A receptors in living Sprague-Dawley rat brains by a novel candidate drug for OAB, E2110, using positron emission tomography (PET) imaging, and assessed the utility of a receptor occupancy (RO) assay to establish a pharmacodynamic index translatable between animals and humans."( A small-animal pharmacokinetic/pharmacodynamic PET study of central serotonin 1A receptor occupancy by a potential therapeutic agent for overactive bladder.
Higuchi, M; Ishihara, H; Maeda, J; Nakatani, Y; Sakai, M; Suhara, T; Suzuki, M; Takenaka, O; Tokunaga, M; Yoshinaga, T; Zhang, MR, 2013
)
0.39

Bioavailability

ExcerptReferenceRelevance
"Anthranilamide analogues such as 23 are potent and highly selective muscarinic M2 antagonists that also show good oral bioavailability and in vivo activity."( Muscarinic M2 antagonists: anthranilamide derivatives with exceptional selectivity and in vivo activity.
Billard, W; Binch, H; Chen, LY; Clader, JW; Crosby, G; Duffy, RA; Ford, J; Greenlee, WJ; Kozlowski, JA; Lachowicz, JE; Li, S; Liu, C; McCombie, SW; Vice, S; Zhou, G, 2004
)
0.32
" Agonistic 5-HT(1A) receptor activity was confirmed in vivo in the ultrasonic vocalization test, and the results suggest that the introduction of the carboxamide residue leads to better bioavailability than the corresponding methyl ether."( Indolebutylamines as selective 5-HT(1A) agonists.
Bartoszyk, GD; Böttcher, H; Greiner, HE; Heinrich, T; Seyfried, CA; Van Amsterdam, C, 2004
)
0.32
"SAR and DMPK studies led to the identification of substituted N-alkyl-N-[1-(3,3-diphenylpropyl)piperidin-4-yl]-2-phenylacetamides as potent and orally bioavailable ligands for the human CCR5 chemokine receptor."( Modulators of the human CCR5 receptor. Part 2: SAR of substituted 1-(3,3-diphenylpropyl)-piperidinyl phenylacetamides.
Cooper, AE; Cumming, JG; Grime, K; Logan, CJ; McLaughlin, S; Oldfield, J; Shaw, JS; Tucker, H; Whittaker, D; Winter, J, 2005
)
0.33
" One of these compounds, 13g, shows modest oral bioavailability in rats."( A new class of bradykinin 1 receptor antagonists containing the piperidine acetic acid tetralin core.
Askew, BC; Biddlecome, G; Biswas, K; Chen, JJ; D'Amico, DC; Fotsch, C; Groneberg, RD; Han, NB; Hsieh, FY; Johnson, E; Kamassah, A; Kumar, G; Lester-Zeiner, D; Liu, Q; Mareska, DA; Ng, G; Riahi, BB; Wang, YJ; Yang, K; Zhan, J; Zhu, J, 2006
)
0.57
" The optimized formulation was evaluated for preclinical bioavailability and antihypertensive efficacy using albino rat model."( Transdermal therapeutic system of enalapril maleate using piperidine as penetration enhancer.
Ahmad, FJ; Ali, MM; Aqil, M; Chowdhary, I; Sultana, Y; Talegaonkar, S, 2008
)
0.59
" Compound 30 showed good oral bioavailability and brain penetration across species."( Discovery of 1,4-substituted piperidines as potent and selective inhibitors of T-type calcium channels.
Adarayan, ED; Ballard, JE; Barrow, JC; Bock, MG; Bunting, PB; Connolly, TM; DiLella, AG; Doran, SM; Fox, SV; Graufelds, VK; Hartman, GD; Koblan, KS; Kraus, RL; Kuo, Y; Lindsley, CW; Magee, MM; Marino, MJ; Nuss, CE; Prueksaritanont, T; Renger, JJ; Reynolds, IJ; Rittle, KE; Schlegel, KA; Shipe, WD; Shu, Y; Tang, C; Uebele, VN; Vargas, HM; Woltmann, RF; Yang, FV; Yang, ZQ; Zrada, MM, 2008
)
0.64
"Design, synthesis, and SAR of a series of 3H-spiro[isobenzofuran-1,4'-piperidine] based compounds as potent, selective and orally bioavailable melanocortin subtype-4 receptor (MC4R) agonists are disclosed."( Discovery of potent, selective, and orally bioavailable 3H-spiro[isobenzofuran-1,4'-piperidine] based melanocortin subtype-4 receptor agonists.
Bakshi, RK; Ball, RG; Chen, AS; Chen, HY; Dellureficio, JP; Dobbelaar, PH; Fong, TM; Guo, L; He, S; Hong, Q; Jian, T; Liu, J; MacIntyre, DE; MacNeil, T; Martin, WJ; Nargund, RP; Peng, Q; Sebhat, IK; Strack, AM; Tamvakopoulos, C; Tang, R; Tsou, NN; Weinberg, DH; Wyvratt, MJ; Ye, Z, 2010
)
0.82
"An oral bioavailability issue encountered during the course of lead optimization in the renin program is described herein."( Impact of passive permeability and gut efflux transport on the oral bioavailability of novel series of piperidine-based renin inhibitors in rodents.
Bleasby, K; Chefson, A; Chen, A; Dubé, D; Ducharme, Y; Fournier, PA; Gagné, S; Gallant, M; Grimm, E; Hafey, M; Han, Y; Houle, R; Lacombe, P; Laliberté, S; Lévesque, JF; MacDonald, D; Mackay, B; Papp, R; Tschirret-Guth, R, 2011
)
0.58
" Together, these data suggest that CP-945,598 is well absorbed and eliminated largely by CYP3A4/3A5-catalyzed metabolism."( Excretion, metabolism, and pharmacokinetics of 1-(8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl)-4-(ethylamino)piperidine-4-carboxamide, a selective cannabinoid receptor antagonist, in healthy male volunteers.
Liras, J; Miao, Z; Prakash, C; Sun, H, 2012
)
0.59
" Bioavailability was optimised by modulation of physico-chemical properties and physical form to deliver a compound suitable for clinical evaluation."( The discovery of CCR3/H1 dual antagonists with reduced hERG risk.
Bahl, A; Barton, P; Bowers, K; Brough, S; Evans, R; Luckhurst, CA; Mochel, T; Perry, MW; Rigby, A; Riley, RJ; Sanganee, H; Sisson, A; Springthorpe, B, 2012
)
0.38
" The systemic exposure level and bioavailability after oral administration of 43 were also good in dog."( Piperidine derivatives as nonprostanoid IP receptor agonists 2.
Hayashi, R; Ishigaki, T; Isogaya, M; Ito, H; Miyamoto, M; Morita, Y, 2016
)
1.88
" Since 3 showed unacceptably low bioavailability (BA) in rats, structural modification, using SBDD and focused on physicochemical properties was conducted to improve its PK profile while maintaining renin inhibitory activity."( Discovery of benzimidazole derivatives as orally active renin inhibitors: Optimization of 3,5-disubstituted piperidine to improve pharmacokinetic profile.
Behnke, CA; Fukase, Y; Imaeda, Y; Iwanaga, K; Kajimoto, Y; Kanagawa, R; Kondo, M; Kuroita, T; Kusumoto, K; Matsuda, K; Snell, G; Taya, N; Tokuhara, H; Watanabe, K, 2018
)
0.69

Dosage Studied

ExcerptRelevanceReference
" Some differences in side-effects at equi-analgesic dosage were observed, particularly a reduction in histamine release."( Pharmacological actions of two new pethidine analogues.
LISTER, RE, 1960
)
0.24
" Compounds 19 and 28, two of the more potent compounds identified in this study, were characterized by high exposure in the brain and demonstrated robust efficacy when dosed in diet-induced obese mice."( Aminopiperidine indazoles as orally efficacious melanin concentrating hormone receptor-1 antagonists.
Brodjian, S; Brune, M; Bush, E; Collins, CA; Dayton, B; Engstrom, KM; Falls, DH; Freeman, JC; Gao, J; Hernandez, LE; Kym, PR; Lynch, JK; Marsh, KC; Mulhern, MM; Shapiro, RD; Souers, AJ; Vasudevan, A; Verzal, MK; Wagaw, SH; Wodka, D, 2005
)
0.84
"9nM) showed a good pharmacokinetic profile upon oral dosing at 10mg/kg in Sprague-Dawley (SD) rats."( Synthesis and pharmacological evaluation of novel N-aryl-3,4-dihydro-1'H-spiro[chromene-2,4'-piperidine]-1'-carboxamides as TRPM8 antagonists.
Bhosale, VM; Chaudhari, SS; Gudi, GS; Kadam, AB; Karnik, PV; Khairatkar-Joshi, N; Mukhopadhyay, I; Raghuram, A; Rao, SS; Sangana, RR; Thomas, A; Vaiyapuri, TS; Wale, DP, 2013
)
0.61
" We used piperidine18 (Pip18), a potent and selective GluN2B-NMDAR antagonist with favorable pharmacokinetic properties, for long-term dosing in AD mouse models."( Chronic GluN2B antagonism disrupts behavior in wild-type mice without protecting against synapse loss or memory impairment in Alzheimer's disease mouse models.
Gogineni, A; Hanson, JE; Herrington, J; Meilandt, WJ; Reynen, P; Scearce-Levie, K; Weimer, RM; Zhou, Q, 2014
)
0.82
" We also demonstrate that upon acute and chronic dosing in rats, 43, a potent cyclopentyl fused pyrrolidine antagonist, reduced circulating plasma RBP4 protein levels by approximately 60%."( Design, synthesis, and evaluation of nonretinoid retinol binding protein 4 antagonists for the potential treatment of atrophic age-related macular degeneration and Stargardt disease.
Barnes, KD; Chen, P; Cioffi, CL; Conlon, MP; Cywin, CL; Dobri, N; Freeman, EE; Golden, KC; Johnson, G; Kitchen, DB; Martin, WH; Michelotti, E; Pearson, PG; Petrukhin, K; Qin, Q; Racz, B; Schwarz, DM; Stafford, DG; Zhu, L, 2014
)
0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (7)

RoleDescription
reagentA substance used in a chemical reaction to detect, measure, examine, or produce other substances.
protic solventA polar solvent that is capable of acting as a hydron (proton) donor.
baseA molecular entity having an available pair of electrons capable of forming a covalent bond with a hydron (Bronsted base) or with the vacant orbital of some other molecular entity (Lewis base).
catalystA substance that increases the rate of a reaction without modifying the overall standard Gibbs energy change in the reaction.
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
non-polar solventnull
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
piperidines
saturated organic heteromonocyclic parent
azacycloalkane
secondary amineA compound formally derived from ammonia by replacing two hydrogen atoms by hydrocarbyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
estrogen nuclear receptor alphaHomo sapiens (human)Potency63.85360.000229.305416,493.5996AID743075
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (10)

Processvia Protein(s)Taxonomy
monoatomic ion transportProton-coupled amino acid transporter 1Homo sapiens (human)
amino acid transportProton-coupled amino acid transporter 1Homo sapiens (human)
taurine transmembrane transportProton-coupled amino acid transporter 1Homo sapiens (human)
proline transportProton-coupled amino acid transporter 1Homo sapiens (human)
alanine transportProton-coupled amino acid transporter 1Homo sapiens (human)
amino acid import across plasma membraneProton-coupled amino acid transporter 1Homo sapiens (human)
glycine transportProton-coupled amino acid transporter 1Homo sapiens (human)
proline transmembrane transportProton-coupled amino acid transporter 1Homo sapiens (human)
proton transmembrane transportProton-coupled amino acid transporter 1Homo sapiens (human)
L-alanine transportProton-coupled amino acid transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (9)

Processvia Protein(s)Taxonomy
amino acid:proton symporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
proline:proton symporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
taurine transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
protein bindingProton-coupled amino acid transporter 1Homo sapiens (human)
amino acid transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
alanine transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
L-alanine transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
L-proline transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
glycine transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
lysosomal membraneProton-coupled amino acid transporter 1Homo sapiens (human)
endoplasmic reticulumProton-coupled amino acid transporter 1Homo sapiens (human)
plasma membraneProton-coupled amino acid transporter 1Homo sapiens (human)
apical plasma membraneProton-coupled amino acid transporter 1Homo sapiens (human)
vacuolar membraneProton-coupled amino acid transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (18)

Assay IDTitleYearJournalArticle
AID1672276Acid dissociation constant, pKa of the compound2019ACS medicinal chemistry letters, Mar-14, Volume: 10, Issue:3
Second Generation Inhibitors of HIV-1 Maturation.
AID781325pKa (acid-base dissociation constant) as determined by Liao ref: J Chem Info Model 20092014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID30386Compound was evaluated for ability to enhance the binding of (+/-)-[3H]nicotine to the rat brain P2 fraction at binding site 1; 10e-9-10e-61985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID1168642Antimicrobial activity against Bacillus cereus NRRL-B-3711 after 18 hrs by agar well diffusion assay2014European journal of medicinal chemistry, Nov-24, Volume: 87Phosphorus-nitrogen compounds. Part 29. Syntheses, crystal structures, spectroscopic and stereogenic properties, electrochemical investigations, antituberculosis, antimicrobial and cytotoxic activities and DNA interactions of ansa-spiro-ansa cyclotetrapho
AID1419135Covalent reactivity with N-alpha-acetyl-L-lysine assessed as half life2018Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23
Identification of Cyanamide-Based Janus Kinase 3 (JAK3) Covalent Inhibitors.
AID342464Dissociation constant, pKa of the compound2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
The many roles for fluorine in medicinal chemistry.
AID30389Ability to enhance the binding of (+/-)-[3H]nicotine to the rat brain P2 fraction at binding site 21985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID1168627Antimicrobial activity against Escherichia coli ATCC 25922 after 18 hrs by agar well diffusion assay2014European journal of medicinal chemistry, Nov-24, Volume: 87Phosphorus-nitrogen compounds. Part 29. Syntheses, crystal structures, spectroscopic and stereogenic properties, electrochemical investigations, antituberculosis, antimicrobial and cytotoxic activities and DNA interactions of ansa-spiro-ansa cyclotetrapho
AID30528Compounds was evaluated for their ability to enhance (+/-)-[3H]nicotine binding at a dose range 10 E -9 - 10 E -6 M was reported1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID781327pKa (acid-base dissociation constant) as determined by Morgenthaler ref: ChemMedChem 20072014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID213129Inhibition of Thromboxane synthetase at 100 uM1981Journal of medicinal chemistry, Oct, Volume: 24, Issue:10
Highly selective inhibitors of thromboxane synthetase. 2. Pyridine derivatives.
AID30377Maximum percent of enhancement of binding.1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID701844Dissociation constant, pKa of the compound2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Mitigating heterocycle metabolism in drug discovery.
AID25336Association constant was determined2004Bioorganic & medicinal chemistry letters, Apr-05, Volume: 14, Issue:7
Syntheses and structure-activity relationship studies of piperidine-substituted quinolones as nonpeptide gonadotropin releasing hormone antagonists.
AID630741Inhibition of human PAT1-mediated L-[3H]proline uptake in human Caco2 cells after 10 mins by liquid scintillation counting2011Bioorganic & medicinal chemistry, Nov-01, Volume: 19, Issue:21
Three-dimensional quantitative structure-activity relationship analyses of substrates of the human proton-coupled amino acid transporter 1 (hPAT1).
AID30391Ability to enhance the binding of (+/-)-[3H]nicotine to the rat brain P2 fraction at binding site 3.1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID30378Maximum percent of inhibition of binding was determined1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID1081643Phytotoxicity against Echinochloa crus-galli (barnyard grass) assessed as mortality measured after 3 days at 5 mg/ml by foliar spraying2010Journal of agricultural and food chemistry, Sep-22, Volume: 58, Issue:18
Phytotoxicity of sarmentine isolated from long pepper (Piper longum) fruit.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (771)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990157 (20.36)18.7374
1990's59 (7.65)18.2507
2000's198 (25.68)29.6817
2010's299 (38.78)24.3611
2020's58 (7.52)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 74.94

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index74.94 (24.57)
Research Supply Index6.69 (2.92)
Research Growth Index4.81 (4.65)
Search Engine Demand Index132.63 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (74.94)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews20 (2.49%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other784 (97.51%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 1 Trial of Brentuximab Vedotin Plus Lenalidomide in Patients With Relapsed/ Refractory Cutaneous T-Cell Lymphomas [NCT03373305]Phase 10 participants (Actual)Interventional2019-03-31Withdrawn(stopped due to contract not executed)
A Phase I Study of Venetoclax + Lenalidomide + Rituximab Hyaluronidase in Relapsed or Refractory (R/R) Indolent Non-Hodgkin's Lymphoma (iNHL). [NCT04447716]Phase 130 participants (Anticipated)Interventional2020-10-16Recruiting
A Pilot Study of 68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU or HDR Therapy [NCT03949517]Phase 1/Phase 210 participants (Anticipated)Interventional2019-04-09Suspended(stopped due to Business decision)
Impact of the Administration of Intravenous or Paravertebral Lidocaine in Continuous Perfusion During the Intraoperative Period of Lung Resection Surgery on the Appearance of Postoperative Complications [NCT03905837]Phase 4156 participants (Actual)Interventional2019-01-28Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]